Loading
CCND3 (G1/S-specific cyclin-D3) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 4 more.
Regulatory component of the cyclin D3-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase.
CIViC holds 5 clinical evidence items and 0 assertions across 3 variants, naming Palbociclib. Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes affected pathway 0.61, literature 0.93, genetic association 0.00, somatic mutation 0.97, animal model 0.47). IntOGen calls it a driver in 5 cohorts (3 activating, 2 loss-of-function), covering Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma.
In plain words · CCND3 (G1/S-specific cyclin-D3) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 4 more.
CCND3 (G1/S-specific cyclin-D3) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Leukaemia, Breast cancer and 4 more.
Regulatory component of the cyclin D3-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition.
No product in this corpus aims at CCND3 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA CCND3: RNA tissue enhanced (lymphoid tissue 239 nTPM); high antibody staining in 6 normal tissues; highest cancer staining carcinoid (2 of 4 high). Distribution: 4 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lymphoma, Leukaemia, Breast cancer (all types), Lung cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P30281; CIViC gene CCND3; IntOGen CCND3; Human Protein Atlas CCND3 tissue; Open Targets ENSG00000112576 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Xiong et al, Genomics, 1992, "Molecular cloning and chromosomal mapping of CCND genes encoding human D-type cyclins". Source.
Sources: HGNC HGNC:1585 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P30281 (protein name, function text, keywords and locations (REST API)); CIViC gene CCND3 (5 evidence items, 0 assertions, 3 variants; diseases: T-cell Lymphoblastic Leukaemia/lymphoma, Diffuse Large B-cell Lymphoma, Lung Squamous Cell Carcinoma, Burkitt Lymphoma, Cancer (GraphQL API, CC0)); Open Targets ENSG00000112576 (association with cancer (MONDO_0004992) 0.65; per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.51, diffuse large B-cell lymphoma 0.55, non-Hodgkin lymphoma 0.69, breast cancer 0.53, leukaemia 0.54 (GraphQL API, CC0)); IntOGen CCND3 (driver in 5 cohorts (Act 3, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Regulatory component of the cyclin D3-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Component of the ternary complex, cyclin D3/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. Shows transcriptional coactivator activity with ATF5 independently of CDK4. Location: Nucleus; Cytoplasm (UniProt). Locus 6p21.1 (HGNC).
RNA: tissue enhanced (lymphoid tissue 239 nTPM), detected in all normal tissues.
Medium: Adrenal gland, Cerebral cortex, Gallbladder, Lung, Placenta, Spleen, Urinary bladder.
Medium only: breast cancer, cervical cancer, colorectal cancer, lung cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CCND3" OR ABSTRACT:"CCND3" OR TITLE:"cyclin D3" OR ABSTRACT:"cyclin D3" OR TITLE:"G1/S-specific cyclin-D3" OR ABSTRACT:"G1/S-specific cyclin-D3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CCND3, not a curated reading list.
Shares The cell-cycle engine (cyclins & CDKs), B-cell receptor / BTK signalling (to NF-κB), Burkitt lymphoma, PI3K / AKT / mTOR.
Shares The cell-cycle engine (cyclins & CDKs), B-cell receptor / BTK signalling (to NF-κB), Burkitt lymphoma, PI3K / AKT / mTOR.
Shares Burkitt lymphoma, Leukaemia (all types), Acute lymphoblastic leukaemia, IntOGen.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, CIViC, IntOGen.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, CIViC, IntOGen.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, CIViC, IntOGen.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, CIViC, Breast cancer (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, CIViC, IntOGen.